News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cosmo Pharmaceuticals S.p.A. to Launch Phase III Trails on Diarrhoea Drug Rifamycin
November 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Cosmo Pharmaceuticals SpA said it is preparing phase III trails for its treatment for infectious diarrhoea, Rifamycin SV MMX, after previous trails proved successful.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
CAR-T
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
September 1, 2026
·
3 min read
·
Tristan Manalac
Cardiovascular disease
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
August 31, 2026
·
3 min read
·
Tristan Manalac
Cancer
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
August 28, 2026
·
2 min read
·
Heather McKenzie
cardiovascular disease
‘Worse than expected’ Wainua data muddies water for TTR silencers
August 28, 2026
·
2 min read
·
Gabrielle Masson
